Below you will find information from the register publication of inside information. The information has been provided by the organisation.
- Registration date 25 may 2016 - 22:00
- Statutory name Galapagos N.V.
- Title FITZROY Phase 2 study with filgotinib in Crohn's Disease presented as late breaker at DDW 2016
- Comments Mechelen, Belgium; 25 May 2016, 22.00 CET: Galapagos (Euronext & NASDAQ: GLPG) announces the presentation of detailed results from the Phase 2 FITZROY study of filgotinib in Crohn's Disease, at Digestive Disease Week (DDW) 2016 in San Diego, CA, USA, held from 21-24 May. More information can be found at www.ddw.org.
|201605250000000015_FITZROY F2 studie in Crohn 'late breaker' op DDW.pdf|
|201605250000000015_FITZROY Ph2 study in CD late breaker at DDW.pdf|
Date last update: 28 January 2021